Compare DCGO & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCGO | NSPR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 72.1M |
| IPO Year | 2020 | 2009 |
| Metric | DCGO | NSPR |
|---|---|---|
| Price | $0.50 | $0.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.38 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 667.9K | 157.9K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $322,196,000.00 | $2,310,000.00 |
| Revenue This Year | N/A | $57.98 |
| Revenue Next Year | $6.77 | $95.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.49 | $0.69 |
| 52 Week High | $1.78 | $2.93 |
| Indicator | DCGO | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.18 | 28.64 |
| Support Level | N/A | $0.69 |
| Resistance Level | $0.65 | $1.04 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 11.48 | 3.37 |
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has two reporting segments: Mobile Health Services and Transportation Services. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.